Press-release for stocks

| -0.84% | O: 0.14% H: 1.05% C: -0.99%
yescarta treatment for t-cell granted authorization therapy

Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma
Published: 2022-06-27 (Crawled : 01:00) - prnewswire.com
KPTI | $4.58 -8.95% 5.02% |

| -11.75% | O: -0.58% H: 2.33% C: -2.52%
collaboration trial

Novel T-Cell Immunotherapies Market - Future Pipeline/Clinical Trial Analysis and Revenue Forecast Snapshot - Exclusive Report by InsightAce Analytic
Published: 2022-06-23 (Crawled : 08:00) - prnewswire.com
TAK | $13.86 -1.42% 0.0% |

| 2.97% | O: 1.56% H: 0.73% C: 0.44%
LLY | News S | $317.62 -2.95% -0.07% |

| 10.11% | O: 4.14% H: 0.0% C: 0.0%
report t-cell trial market

Kiromic BioPharma Pipeline to Prioritize a New Gamma Delta T-cell Product Candidate
Published: 2022-06-21 (Crawled : 13:00) - biospace.com/
KRBP | $0.455 -7.16% -0.66% |

| 13.55% | O: 23.76% H: 0.0% C: 0.0%
biopharma candidate t-cell

European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy
Published: 2022-06-20 (Crawled : 12:00) - biospace.com/
BMY | $78.7 -1.6% 1.19% |

| Email alert Add to watchlist
for application therapy

Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme DiseaseT-Detect Lyme
Published: 2022-06-15 (Crawled : 12:20) - biospace.com/
ADPT | $8.24 -4.19% 0.0% |

| 30.38% | O: 4.11% H: 11.78% C: 8.66%
for test t-cell

IASO Bio and Innovent Present Updated Data of BCMA CAR-T Cell Therapy (Equecabtagene Autoleucel) at EHA 2022
Published: 2022-06-13 (Crawled : 02:00) - prnewswire.com
LLY | News S | $317.62 -2.95% -0.07% |

| 8.96% | O: -3.12% H: 0.0% C: 0.0%
INCY | News | $75.63 -2.24% -0.99% |

| 7.99% | O: -3.69% H: 0.0% C: 0.0%
car-t therapy

Innovent and IASO Bio Present Updated Data of BCMA CAR-T Cell Therapy (Equecabtagene Autoleucel) at EHA 2022
Published: 2022-06-13 (Crawled : 01:00) - prnewswire.com
LLY | News S | $317.62 -2.95% -0.07% |

| 8.96% | O: -3.12% H: 0.0% C: 0.0%
INCY | News | $75.63 -2.24% -0.99% |

| 7.99% | O: -3.69% H: 0.0% C: 0.0%
car-t therapy

Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL
Published: 2022-06-12 (Crawled : 12:20) - globenewswire.com
NVSEF | News | $84.85 1.0% |

| Email alert Add to watchlist
NVS | News | $84.17 -1.3% -0.18% |

| Email alert Add to watchlist
kymriah children novartis

AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) at the European Hematology Association (EHA) Annual Congress
Published: 2022-06-11 (Crawled : 16:20) - prnewswire.com
ABBV | News | $152.49 -0.42% 0.41% |

| Email alert Add to watchlist
cd20 duobody trial results

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium
Published: 2022-06-11 (Crawled : 16:20) - globenewswire.com
GMAB | $31.44 -2.93% 0.0% |

| Email alert Add to watchlist
GNMSF | $315.375 -1.74% |

| Email alert Add to watchlist
cd20 duobody symposium trial results

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress
Published: 2022-06-11 (Crawled : 16:20) - globenewswire.com
CRSP | $63.28 -5.41% 0.11% |

| Email alert Add to watchlist
ctx130 crispr trial therapeutics positive results

GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress
Published: 2022-06-10 (Crawled : 12:20) - globenewswire.com
GTBP | $2.96 2.42% 0.0% |

| -0.67% | O: 2.01% H: 0.0% C: 0.0%
cd19 trike biopharma preclinical

Caribou Biosciences Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress
Published: 2022-06-10 (Crawled : 08:00) - globenewswire.com
CRBU | $5.68 -2.24% 3.35% |

| -36.29% | O: -22.27% H: 0.0% C: 0.0%
cb-010 car-t trial positive therapy

Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma
Published: 2022-06-08 (Crawled : 13:00) - allogene.com
ALLO S | $11.48 -1.88% 0.0% |

| 41.38% | O: 15.39% H: 13.02% C: 11.63%
allo-501 fda designation for granted therapeutics therapy

AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients
Published: 2022-06-07 (Crawled : 13:20) - biospace.com/
ALVR | $4.1 -2.38% 0.0% |

| 5.67% | O: -1.55% H: 7.85% C: 4.71%
treatment ongoing for kidney

Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer
Published: 2022-06-07 (Crawled : 12:00) - immatics.com
IMTX | $8.56 -3.28% 0.0% |

| 8.91% | O: 3.69% H: 4.66% C: 2.45%
treatment research for collaboration cancer

Kiromic BioPharma Significantly Expands Gamma Delta T cell Product Pipeline with New Sponsored Research Agreement
Published: 2022-06-07 (Crawled : 12:00) - biospace.com/
KRBP | $0.455 -7.16% -0.66% |

| 51.67% | O: 100.0% H: 7.17% C: -16.33%
biopharma research

Yescarta® CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity
Published: 2022-06-03 (Crawled : 22:00) - biospace.com/
GILD | News | $62.21 -0.99% -0.31% |

| -3.79% | O: -2.01% H: 0.0% C: 0.0%
yescarta t-cell therapy

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Peripheral T-Cell Lymphoma
Published: 2022-06-01 (Crawled : 13:00) - globenewswire.com
KYMR | $19.67 -5.11% -4.98% |

| 28.56% | O: -1.11% H: 6.01% C: -6.61%
kt-333 treatment fda designation drug for t-cell therapeutics

← Previous
1
2
3
4
5
6
7
8
9
…
16
17
Next →

Your saved searches

Save your searches and get alerts when important news are released.

Mentioned Today

ABB | News | $26.87 -0.85% 0.48% |

ABLZF | News | $28.0 1.08% |

ACN | News | $283.8 -3.01% -1.34% |

AIH | News | $1.95 0.52% -2.05% |

Health Services

AKAM | News | $92.39 -2.25% 0.5% |

ALPMF | News | $16.71 5.56% |

ALPMY | News | $16.14 1.19% |

APH | News | $64.72 -2.12% 0.0% |

ARVL | News | $1.61 -4.73% 0.0% |

AUOTY | News | $6.01 1.01% |

AVAV | News | $81.71 -1.35% -10.66% |

AXON | News | $95.0 -1.85% 3.39% |

BHC | News 4 | $8.83 1.73% -0.57% |

BNPQF | News | $49.65 -4.65% |

BNPQY | News | $24.99 -0.99% |

Finance and Insurance

BNPZY | News | $ 0% |

Finance and Insurance

BTG | News | $3.55 -3.01% 1.13% |

Non-Energy Minerals

CERN | News | $94.92 0.03% |

CGNT | News | $4.58 -28.66% 2.4% |

CGNX | News | $44.63 -1.85% -2.31% |

CLH | News | $87.8 0.92% 0.0% |

CNF | News | $3.21 -4.46% 0.0% |

COLD | News | $30.06 -0.76% 0.0% |

COP | News | $95.22 3.24% -0.23% |

Energy Minerals

CRCW | News | $0.965 1.58% |

Information

CREE | News | $80.07 0% |

CRM | News 4 | $171.46 -5.43% -0.26% |

CSCO | News | $43.06 -1.62% 0.09% |

CTXS | News | $96.15 -0.63% 0.0% |

CVLT | News | $63.29 -2.78% 0.0% |

CW | News | $131.15 -0.67% 0.0% |

DELL | News | $48.94 -2.59% 0.0% |

DGII | News | $23.3 -4.04% 0.0% |

DHR | News | $251.88 -1.77% 0.0% |

DKILF | News | $157.75 -5.18% |

DKILY | News | $16.18 0.81% |

ECOM | News | $14.68 1.17% 4.97% |

ERIC | News | $7.78 -2.14% -0.39% |

ESLT | News | $210.38 1.14% 0.0% |

ETNB | News | $3.55 3.2% -4.79% |

EVH | News | $30.94 -2.74% 0.0% |

FANH | News | $5.15 -1.91% 1.17% |

FCN | News | $172.21 -1.22% 0.0% |

FLIR | News | $57.34 0% |

GBERF | News | $546.0 |

GBERY | News | $48.7 -1.6% |

GE | News | $65.88 -1.24% -0.47% |

GLAXF | News | $21.99 4.22% |

GLPI | News | $46.68 -0.09% -3.06% |

GSK | News | $43.35 -0.8% -0.42% |

GXO | News | $45.5 -1.22% 2.13% |

HLF | News | $22.86 -2.52% 0.0% |

Distribution Services

HNI | News | $35.65 -2.33% 0.0% |

HON | News | $175.95 -1.31% 0.03% |

HY | News | $33.35 -3.42% 0.0% |

IKTSF | News | $59.175 |

Professional, Scientific, and T...

IKTSY | News | $53.97 0.26% |

INCY | News | $75.63 -2.24% -0.99% |

INTU | News 4 | $386.29 -4.55% 0.0% |

IRCP | News | $2.4984 0.06% |

JCI | News | $48.44 -0.43% 0.0% |

JG | News | $1.09 -0.91% -0.92% |

JTEKF | News | $ 0% |

JTEKY | News | $24.29 |

LEA | News | $134.75 0.57% 0.0% |

LHX | News | $235.82 -0.42% 0.0% |

LII | News | $202.46 -0.42% 0.0% |

LLY | News 4 | $317.62 -2.95% -0.07% |

LMT | News | $420.71 0.35% 0.21% |

MASI | News | $137.07 -1.95% 0.0% |

MCFUF | News | $4.105 |

MCK | News 4 | $321.55 -1.44% -0.02% |

Distribution Services

MDRX | News 4 | $15.33 -2.23% 0.0% |

MDT | News | $89.2 -1.4% -0.1% |

MSFT | News | $256.48 -3.18% 0.06% |

MSI | News | $210.24 -3.17% 1.42% |

MTX | News | $61.47 -0.87% 0.0% |

Process Industries

NAT | News | $2.21 -0.9% -0.45% |

Transportation

NDAQ | News 4 | $154.66 -2.07% -1.61% |

NIO | News | $22.36 -2.57% -8.0% |

Consumer Durables

NIPNF | News | $38.0 |

NOC | News | $464.67 -0.46% 0.74% |

NOK | News | $4.75 -1.45% 0.84% |

NOKBF | News | $4.954 0.41% |

NUAN | News | $55.99 0% |

NUVB | News | $3.55 -2.47% 0.0% |

NVS | News | $84.17 -1.3% -0.18% |

NVSEF | News | $84.85 1.0% |

ORCL | News 4 | $68.58 -2.6% 1.5% |

PCRFF | News | $8.217 0.82% |

n/a

PCRFY | News | $8.16 -0.73% |

n/a

PHI | News | $31.73 1.47% 0.0% |

Communications

PHTCF | News | $30.23 -17.81% |

Communications

PPRUF | News | $544.41 1.95% |

Consumer Non-Durables

PPRUY | News | $52.31 0.13% |

RELX | News | $26.77 -1.91% 0.04% |

RLXXF | News | $26.94 -1.93% |

RNGR | News | $10.28 -0.48% 0.0% |

ROK | News | $197.64 -1.82% 0.0% |

RSG | News 4 | $127.91 -1.15% 0.0% |

RYLPF | News | $21.425 -2.83% |

SAP | News | $95.47 -1.88% -1.02% |

SAPGF | News | $97.382 -1.0% |

SBGSF | News | $124.59 -1.9% |

SBGSY | News | $24.426 -0.99% |

SEKEF | News | $15.184 -6.47% |

SEKEY | News | $7.34 -0.74% |

SNNUF | News | $15.05 4.44% |

TEL | News | $114.92 -2.24% 0.0% |

TEVJF | News | $8.34 0.48% |

TMO | News | $535.77 -1.45% -1.84% |

TRI | News | $101.23 -2.95% 0.0% |

TXT | News | $60.05 -1.22% 0.0% |

UL | News | $45.33 -1.46% -0.13% |

Consumer Non-Durables

UNLYF | News | $45.805 -3.0% |

Consumer Non-Durables

VEON | News | $0.4567 -0.74% 0.42% |

Communications

VMW | News | $116.25 -1.2% 0.0% |

VSH | News | $18.22 -0.92% 0.0% |

VTRS | News | $10.9 -1.54% 1.19% |

VUZI | News | $6.85 2.39% 2.19% |

WFC | News 4 | $40.18 -0.15% 0.17% |

WKEY | News | $2.68 -5.63% 2.24% |

WM | News | $148.88 -0.43% 0.42% |

XYL | News 4 | $77.9 -2.07% 0.0% |

ZIXI | News | $8.48 0% |

ZTS | News 4 | $170.12 -2.01% 0.0% |

ZUO | News 4 | $9.3 -5.3% 0.0% |